Please wait...


Generic Name: dasatinib (da SAT in ib)
Brand Names: Sprycel
Sprycel is used to treat chronic myeloid leukemia and acute lymphoblastic leukemia. Learn about side effects, interactions and indications.
  • Prescription Settings

Prices and coupons of Sprycel

Current Location: 20149 (Ashburn)
Change Location?

Enter your zip code

Please wait while the prices are loaded...

Don’t see your pharmacy listed? Most pharmacies accept our discounts, so have your pharmacist enter this coupon to see if you will save money:

Drug Information:
Sprycel (dasatinib) is a cancer medicine that slows the growth and spread of cancer cells in the body. Sprycel is used in adults and children to treat a type of blood cancer called Philadelphia chromosome-positive chronic myelogenous leukemia (CML). Sprycel is also used to treat Philadelphia chromosome-positive acute lymphoblastic leukemia (ALL) in adults and children. Sprycel is a cancer medication that slows the growth and spread of cancer cells in the body. Sprycel can lower blood cells that help your body fight infections and help your blood to clot. You may get an infection or bleed more easily. Call your doctor if you have unusual bruising or bleeding, or signs of infection (fever, chills, body aches). Learn more

Sprycel Side Effects

Sprycel Side Effects

Note: This document contains side effect information about dasatinib. Some of the dosage forms listed on this page may not apply to the brand name Sprycel.

In Summary

Common side effects of Sprycel include: pericardial effusion, pleural effusion, pulmonary edema, dyspnea, fluid retention, and gastrointestinal hemorrhage. Other side effects include: anasarca. See below for a comprehensive list of adverse effects.

For the Consumer

Applies to dasatinib: oral tablet

Along with its needed effects, dasatinib (the active ingredient contained in Sprycel) may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.

Check with your doctor immediately if any of the following side effects occur while taking dasatinib:

More common

  • Bloody or black, tarry stools
  • body aches or pain
  • burning, tingling, numbness, or pain in the hands, arms, feet, or legs
  • chest pain
  • chills
  • constipation
  • cough
  • coughing up blood
  • decrease in the amount of urine
  • dizziness
  • ear congestion
  • fainting
  • fast, slow, or irregular heartbeat
  • fever
  • full or bloated feeling
  • headache
  • hoarseness
  • loss of voice
  • lower back or side pain
  • nasal congestion
  • noisy or rattling breathing
  • painful or difficult urination
  • pale skin
  • paralysis
  • pressure in the stomach
  • runny nose
  • sensation of pins and needles
  • severe stomach pain
  • sneezing
  • sore throat
  • stabbing pain
  • swelling of the abdominal or stomach area
  • swelling of the face, fingers, hands, feet, or lower legs
  • tightness in the chest
  • troubled breathing
  • ulcers, sores, or white spots in the mouth
  • unsteadiness or awkwardness
  • unusual bleeding or bruising
  • unusual tiredness or weakness
  • vomiting of blood or material that looks like coffee grounds
  • weakness in the arms, hands, legs, or feet
  • weight gain

Less common

  • Blue lips and fingernails
  • chest discomfort
  • coughing that sometimes produces a pink frothy sputum
  • decreased urine output
  • difficult or fast breathing
  • dilated neck veins
  • increased sweating
  • irregular breathing
  • nausea
  • swelling in the legs and ankles

Incidence not known

  • Anxiety
  • pain, redness, or swelling in the arm or leg
  • tenderness, pain, swelling, warmth, skin discoloration, and prominent superficial veins over the affected area

Some side effects of dasatinib may occur that usually do not need medical attention. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects. Check with your health care professional if any of the following side effects continue or are bothersome or if you have any questions about them:

More common

  • Bleeding gums
  • cracked lips
  • diarrhea
  • difficulty with moving
  • difficulty with swallowing
  • increased menstrual flow or vaginal bleeding
  • itching skin or rash
  • lack or loss of strength
  • loss of appetite
  • muscle aching, cramping, or stiffness
  • muscle or bone pain
  • nose bleeds
  • pain
  • pain in the joints
  • prolonged bleeding from cuts
  • red or dark brown urine
  • stomach pain
  • swollen joints
  • vomiting
  • weight loss

For Healthcare Professionals

Applies to dasatinib: oral tablet


In the phase III dose optimization study in patients with chronic phase CML, grade 3 or 4 myelosuppression occurred more frequently in patients treated with the 70 mg twice daily regimen than in those treated with a 100 mg once daily regimen.

Very common (10% or more): Hemorrhage (11 to 26%)

Common (1% to 10%): Febrile neutropenia, pancytopenia

Uncommon (0.1% to 1%): CNS bleeding

Rare (Less than 0.1%): Aplasia pure red cell


The most common side effects included fluid retention, musculoskeletal pain, diarrhea, rash, and headache.


Very common (10% or more): Diarrhea (18 to 31%), vomiting (11 to 16%), nausea (18 to 24%), abdominal pain (12%)

Common (1% to 10%): Enterocolitis infection, gastrointestinal bleeding, neutropenic colitis, gastritis, mucositis, stomatitis, dyspepsia, abdominal distension, constipation, oral soft tissue disorder

Uncommon (0.1% to 1%): Pancreatitis, upper gastrointestinal ulcer, esophagitis, ascites, anal fissure, dysphagia

Rare (Less than 0.1%): Protein-losing gastroenteropathy, ileus

Postmarketing reports: Fatal gastrointestinal hemorrhage

Nervous system

Very common (10% or more): Headache (13 to 33%)

Common (1% to 10%): Neuropathy, peripheral neuropathy, dizziness, dysgeusia, somnolence

Uncommon (0.1% to 1%): Syncope, amnesia, tremor

Rare (Less than 0.1%): Cerebrovascular accident, transient ischemic attack, convulsion, optic neuritis, seventh nerve paralysis


Very common (10% or more): Musculoskeletal pain (11 to 22%)

Common (1% to 10%): Arthralgia, myalgia, muscular weakness, musculoskeletal stiffness, muscle spasm, chills

Uncommon (0.1% to 1%): Rhabdomyolysis, muscle inflammation, tendonitis, blood creatine phosphokinase increased


Very common (10% or more): Pleural effusion (11 to 24%), dyspnea (15 to 24%), cough

Common (1% to 10%): Pneumonia (including bacterial, viral, fungal), upper respiratory tract infection, pulmonary edema, pulmonary hypertension, lung infiltration, pneumonitis

Uncommon (0.1% to 1%): Bronchospasm, asthma

Rare (Less than 0.1%): Acute respiratory distress syndrome

Postmarketing reports: Pulmonary embolism, interstitial lung disease, pulmonary arterial hypertension


Common (1% to 10%): Anorexia, appetite disturbances, hyperuricemia, weight decreased, weight increased

Uncommon (0.1% to 1%): Hypoalbuminemia


Uncommon (0.1% to 1%): Hepatitis, cholecystitis, cholestasis


Common (1% to 10%): Congestive heart failure, cardiac dysfunction, pericardial effusion, arrhythmia, tachycardia, palpitations, hypertension, chest pain

Uncommon (0.1% to 1%): Myocardial infarction, electrocardiogram QT prolongation, pericarditis, ventricular arrhythmia, ventricular tachycardia, angina pectoris, cardiomegaly, hypotension

Rare (less than 0.1%): Cor pulmonale, myocarditis, acute coronary syndrome

Postmarketing reports: Atrial fibrillation, atrial flutter

Results from phase II single arm clinical studies of 911 patients reported QT prolongation in 9 patients. Three patients (less than 1%) experienced a QTcF greater than 500 milliseconds.

In the phase III dose optimization study in patients with chronic phase CML, pleural effusion and congestive cardiac failure/cardiac dysfunction occurred more frequently in the 70 mg twice a day regimen than in those treated with a 100 mg once daily regimen.


Very common (10% or more): Skin rash (15 to 21%)

Common (1% to 10%): Flushing, alopecia, dermatitis, eczema, pruritus, acne, dry skin, urticaria, hyperhidrosis, contusion

Uncommon (0.1% to 1%): Acute febrile neutrophilic dermatosis, photosensitivity, pigmentation disorder, panniculitis, skin ulcer, bullous conditions, nail disorder, palmar-plantar erythrodysesthesia syndrome

Rare (Less than 0.1%): Livedo reticularis


Very common (10% or more): Fluid retention (21 to 42%)

Uncommon (0.1% to 1%): Renal failure, urinary frequency, proteinuria


Very common (10% or more): Fatigue (19 to 26%), superficial edema (10 to 21%), pyrexia (11 to 18%)

Common (1% to 10%): Tinnitus, pain, generalized edema, asthenia

Uncommon (0.1% to 10%): Vertigo, thrombophlebitis, gynecomastia, irregular menstruation, malaise, temperature intolerance

Postmarketing reports: Deep vein thrombosis


Common (1% to 10%): Depression, insomnia

Uncommon (0.1% to 1%): Anxiety, confusion, affect lability, libido decreased


Uncommon (0.1% to 1%): Erythema nodosum, unspecified hypersensitivity reaction


Common (1% to 10%): Visual disturbance, blurred vision, reduction in visual acuity, dry eye

Uncommon (0.1% to 1%): Conjunctivitis

Rare (Less than 0.1%): Visual impairment


Uncommon (0.1% to 1%): Tumor lysis syndrome


Very common (10% or more): Infection (including bacterial, viral, fungal, non-specified) (10 to 14%)

Common (1% to 10%): Sepsis

Editorial References and Review

Medically reviewed by BestRx Medical Team Last updated on 1/1/2020.

Source: Drugs.com Sprycel